Compare ResMed Inc. (RMD) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Xpeng Inc - ADR — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Xpeng Inc - ADR trades at $10.48 (market cap $10.34B). The key difference: ResMed Inc. is far larger — about 3.1× Xpeng Inc - ADR's market cap, and ResMed Inc. pays a 1.19% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| RMD | XPEV | |
|---|---|---|
Market Cap | $31.89B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $28.07 |
52-Week Low | $182.82 | $10.57 |
Enterprise Value | $31.24B | $12.92B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
XPeng (XPEV) trades at $10.93, down 0.18% on the day, with a bearish technical signal and negative earnings in recent quarters. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, and cash flow trends show volatility. Recent news highlights expansion into humanoid robotics, with the robotics unit raising over $900 million at a $6.3 billion valuation in August 2026.
The outlook is mixed: analyst consensus is bullish with a $19.00 price target, but execution risks in the competitive EV market and persistent losses pose challenges. Robotics diversification offers long-term potential, yet near-term profitability remains uncertain amid weak delivery forecasts and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
